Patents by Inventor Galina Selivanova

Galina Selivanova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azabicyclooctan-3-one derivatives and use thereof
    Patent number: 7759361
    Abstract: Compounds of Formula (1) process for preparing them, pharmaceutical compositions comprising them. The use of compounds of formula (1) for hyperproliferative diseases, e.g. cancer as well as autoimmune diseases and heart disease.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: July 20, 2010
    Assignee: Aprea AB
    Inventors: Jacob Westman, Klas Wiman, Galina Selivanova, Vladimir Bykov
  • Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
    Patent number: 7659278
    Abstract: The present invention provides novel compounds, corresponding to formulae I and II, respectively, which are able to reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is provided by restoration of sequence-specific DNA-binding activity and transcriptional transactivation function to mutant p53 proteins, and modulation of the conformation-dependent epitopes of the p53 protein. Accordingly, the substances according to the invention will be used in pharmaceutical compositions and methods for treatment of patients suffering from various types of tumours.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: February 9, 2010
    Assignee: Aprea AB
    Inventors: Vladimir Bykov, Galina Selivanova, Klas Wiman
  • 1-azabicyclo [2,2,2] octan-3-one derivatives
    Patent number: 7348330
    Abstract: The present invention provides novel compounds, corresponding to formulae I and II, respectively, which are able to reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is provided by restoration of sequence-specific DNA-binding activity and transcriptional transactivation function to mutant p53 proteins, and modulation of the conformation-dependent epitopes of the p53 protein. Accordingly, the substances according to the invention will be used in pharmaceutical compositions and methods for treatment of patients suffering from various types of tumors.
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: March 25, 2008
    Assignee: Aprea AB
    Inventors: Vladimir Bykov, Galina Selivanova, Klas Wiman
  • Azabicyclooctan-3-one derivatives and use thereof
    Publication number: 20070142370
    Abstract: Compounds of Formula (1) process for preparing them, pharmaceutical compositions comprising them. The use of compounds of formula (1) for hyperproliferative diseases, e.g. cancer as well as autoimmune diseases and heart disease.
    Type: Application
    Filed: March 22, 2005
    Publication date: June 21, 2007
    Applicant: APREA AB
    Inventors: Jacob Westman, Klas Wiman, Galina Selivanova, Vladimir Bykov
  • Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53.
    Publication number: 20060276502
    Abstract: The present invention relates to the use of 1-azabicyclo[2.2.2]octanes, capable of transferring wild type p53 from an inactive and non-functional conformation into an active conformation, for the preparation of a pharmaceutical compositions for use in treating medical compositions wherein wt p53 exists in an inactive state defined herein, especially malignant melanoma and conditions involving undesired angiogenesis. The inven-tion also relates to methods of in vivo and in vitro testing of compounds for the above-mentioned ability, wherein inactive wt p53 is monitored or detected.
    Type: Application
    Filed: March 23, 2004
    Publication date: December 7, 2006
    Inventors: Staffan Stromblad, Wenije Bao, Galina Selivanova, Natalia Issaeva
  • 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
    Patent number: 6921765
    Abstract: The present invention provides novel compounds, corresponding to formulae I and II, respectively, which are able to reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is provided by restoration of sequence-specific DNA-binding activity and transcriptional transactivation function to mutant p53 proteins, and modulation of the conformation-dependent epitopes of the p53 protein. Accordingly, the substances according to the invention will be used in pharmaceutical compositions and methods for treatment of patients suffering from various types of tumors.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: July 26, 2005
    Assignee: Aprea AB
    Inventors: Vladimir Bykov, Galina Selivanova, Klas Wiman
  • 1-Azabicyclo [2,2,2] octan-3-one derivatives
    Publication number: 20050090540
    Abstract: The present invention provides novel compounds, corresponding to formulae I and II, respectively, which are able to reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is provided by restoration of sequence-specific DNA-binding activity and transcriptional transactivation function to mutant p53 proteins, and modulation of the conformation-dependent epitopes of the p53 protein. Accordingly, the substances according to the invention will be used in pharmaceutical compositions and methods for treatment of patients suffering from various types of tumors.
    Type: Application
    Filed: December 14, 2004
    Publication date: April 28, 2005
    Applicant: APREA AB
    Inventors: Vladimir Bykov, Galina Selivanova, Klas Wiman
  • Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
    Publication number: 20050090510
    Abstract: The present invention provides novel compounds, corresponding to formulae I and II, respectively, which are able to reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is provided by restoration of sequence-specific DNA-binding activity and transcriptional transactivation function to mutant p53 proteins, and modulation of the conformation-dependent epitopes of the p53 protein. Accordingly, the substances according to the invention will be used in pharmaceutical compositions and methods for treatment of patients suffering from various types of tumours.
    Type: Application
    Filed: February 7, 2003
    Publication date: April 28, 2005
    Inventors: Vladimir Bykov, Galina Selivanova, Klas Wiman
  • 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
    Publication number: 20030166674
    Abstract: The present invention provides novel compounds, corresponding to formulae I and II, respectively, which are able to reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is provided by restoration of sequence-specific DNA-binding activity and transcriptional transactivation function to mutant p53 proteins, and modulation of the conformation-dependent epitopes of the p53 protein. Accordingly, the substances according to the invention will be used in pharmaceutical compositions and methods for treatment of patients suffering from various types of tumors.
    Type: Application
    Filed: March 20, 2003
    Publication date: September 4, 2003
    Inventors: Vladimir Bykov, Galina Selivanova, Klas Wiman